Junshi Biosciences Back in the Red, Pins Hopes on Covid Drugs

The innovative drug developer reported a first-quarter loss as a result of a steep drop in licensing revenue Key Takeaways: Junshi Biosciences’ revenue tumbled 61% in the first quarter, reflecting its high dependence on income from overseas licensing The company is hoping for steadier future revenue from an oral Covid-19 drug now in Phase 3 multi-regional clinical trials (MRCTs) By Molly Wen 2021 was a bittersweet year for Shanghai Junshi Biosciences Co. Ltd. (1877.HK; 688180.SH). Its Covid-19 neutralizing antibody drug JS016 was a hit overseas and became a major new…

Read More »

FAST NEWS: Qudian Regains Compliance With New York Listing Rules

The latest: Online lender Qudian Inc. (QD.US) said on Thursday it has regained compliance with New York Stock Exchange listing rules, after its average closing price for the last 30 trading days rose above the $1 mark. The price had previously traded below that level on a similar basis, leading the company to warn in February it was in danger of delisting. Looking Up: The return to compliance means Qudian won’t need to take other steps to avoid delisting. The most typical step companies use in such situations is a…

Read More »

I-Mab Shaken by Management Moves, Merger Talk and Delisting Threat

Cancer drug maker has been in a wide range of market-moving headlines lately, though its stock still trades near an all-time low Key Takeaways: I-Mab was placed on a list of stocks at danger of being delisted from the U.S., just a week after it announced two major new executive appointments Company is reportedly exploring a potential sale to a western pharma giant, or a possible merger with a smaller peer By Shirley Lau There’s no shortage of market-moving news these days about up-and-coming cancer drug maker I-Mab (IMAB.US), whose…

Read More »